高级检索
当前位置: 首页 > 详情页

Lobar versus Sub-Lobar Resection for Clinical Stage IA1-2 Non-Small Cell Lung Cancer with Tumor Spread Through Air Spaces

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Thoracic Surgical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China [2]Department of Cardiothoracic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China [3]Department of Cardiothoracic Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China [4]Department of Thoracic Surgery, Putuo District People’s Hospital, Zhoushan, China [5]Department of Thoracic Surgery, The First Affiliated Hospital of Shaoyang University, Shaoyang, China [6]Department of Integrated Traditional Chinese and Western Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China [7]Department of Thoracic Surgery, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China [8]School of Life Science and Technology, ShanghaiTech University, Shanghai, China. [9]Wenzhou People’s Hospital, Wenzhou, China [10]Department of Cardiothoracic Surgery, Ningbo Beilun District People’s Hospital, Ningbo, China [11]Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
出处:
ISSN:

关键词: Non-small cell lung cancer Spread through air spaces Sub-lobar resection Lobar resection Survival outcomes Adjuvant therapy

摘要:
Controversy persists regarding the efficacy of sub-lobar resection(SR) versus lobar resection(LR) for clinical IA non-small cell lung cancer with tumor spread through air spaces, suggesting that a one-size-fits-all approach may be inappropriate for this heterogeneous population. This study aims to identify the factors potentially modifying the survival benefits of LR over SR in clinical IA spread through air spaces-positive non-small cell lung cancer.Consecutive peripheral clinical IA1-2 spread through air spaces-positive non-small cell lung cancer patients undergoing surgery between 2014 and 2020 at 6 high-volume institutions were retrospectively reviewed. Propensity-score matching was used to mitigate selection bias. The primary endpoint was recurrence-free survival.Among 4555 cases, propensity-score matching resulted in 1238 and 2476 patients in SR and LR groups, respectively, who were used for further investigation. LR yielded better prognoses compared to SR in the overall cohort. Interaction and stratified analyses further revealed that LR significantly improved survival compared to SR in clinical IA2 patients, whereas survival outcomes were comparable between two approaches in clinical IA1 patients. In lymphovascular invasion-negative pathological IA subcohorts, adjuvant therapy improved survival in pathological IA2-3 patients receiving SR, but showed no survival benefit in pathological IA1 patients, or pathological IA2-3 patients undergoing LR.Collectively, clinical IA2 patients may derive greater benefit from LR, while clinical IA1 patients could be considered appropriate candidates for SR. In lymphovascular invasion-negative pathological IA subcohorts, adjuvant therapy could be recommended for pathological IA2-3 patients after SR, while it may not be necessary for those receiving LR or pathological IA1 patients.Copyright © 2025. Published by Elsevier Inc.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 2 区 医学
小类 | 2 区 呼吸系统 2 区 外科 3 区 心脏和心血管系统
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 呼吸系统 2 区 外科 3 区 心脏和心血管系统
第一作者:
第一作者机构: [1]Department of Thoracic Surgical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:29059 今日访问量:0 总访问量:1619 更新日期:2025-10-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)